source
- Scribe secures $129M in a rare gene editing IPOThe startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.BioPharma Dive · 6d ago↗ source
- FDA panel endorses broader use of certain peptidesIn a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supportin…BioPharma Dive · 6d ago↗ source
- Lilly, with new data, to seek FDA approval of obesity drug retatrutideThe new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.